ArticleMediators of inflammation2026
Haikun Shenxi Capsule Alleviates Renal Fibrosis in CKD Mice by Targeting the METTL3/IGF2BP3-Mediated m6A Modification of NKD2.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Haikun Shenxi Capsule Alleviates Renal Fibrosis in CKD Mice by Targeting the METTL3/IGF2BP3-Mediated m6A Modification of NKD2.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRenal fibrosis is a central pathological process in chronic kidney disease (CKD). Although Haikun Shenxi Capsule (HKSX) has shown clinical efficacy in CKD, its precise molecular targets and mechanisms remain unclear.
objectiveThis study aims to determine whether HKSX exerts antifibrotic effects in CKD by modulating NKD2 expression via METTL3-mediated m6A pathway.
methodsA CKD mouse model was established by unilateral ureteral obstruction (UUO). Mice were divided into Sham, Model, low-dose HKSX, high-dose HKSX, and positive drug groups. Renal pathology and fibrosis were assessed by H&E, Masson's trichrome, and Sirius red staining. Renal function was evaluated by measuring serum creatinine (Scr) and blood urea nitrogen (BUN) levels. Inflammatory cytokines, oxidative stress markers, apoptosis-related proteins, fibrotic markers, NKD2, and METTL3 were detected by ELISA, qPCR, and Western blotting. Global m6A levels and NKD2 mRNA-specific m6A enrichment were measured by colorimetric assay and MeRIP-qPCR, respectively. Renal-specific METTL3-overexpressing mice were generated via lentivirus to validate target dependency. The role of the m6A reader IGF2BP3 was investigated using RIP-qPCR.
resultsHKSX significantly improved renal function and attenuated renal pathological injury, inflammation, oxidative stress, apoptosis, and fibrosis in UUO mice. Mechanistically, HKSX dose-dependently downregulated METTL3 expression, reduced both global renal m6A levels and NKD2 mRNA-specific m6A modification, and consequently inhibiting NKD2 overexpression. The protective effects of HKSX were largely abrogated in METTL3-overexpressing CKD mice. Furthermore, HKSX specifically inhibited the expression of the m6A reader IGF2BP3 and its binding to NKD2 mRNA.
conclusionThis study demonstrates that HKSX alleviates renal fibrosis by inhibiting METTL3, which reduces m6A modification on NKD2 mRNA, and by downregulating the stability reader IGF2BP3. These effects collectively decrease NKD2 mRNA stability and protein expression. These findings reveal a novel epitranscriptomic mechanism of HKSX and identify the METTL3/IGF2BP3/NKD2 axis as a key therapeutic pathway in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.